Last reviewed · How we verify
NCT01165762
Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.
Phase 1 trial testing Immune Tolerance in ESRD in 25 participants. Status unknown.
14 June 2024
Quick facts
| Lead sponsor | Everett Meyer |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 14 July 2010 |
| Primary completion | 14 June 2024 |
| Estimated completion | 14 June 2025 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Immune Tolerance — full drug profile →
Conditions studied
- ESRD — all drugs for ESRD →
Sponsor
Everett Meyer — full company profile →
Who can join
Adults 18 to 60, any sex, with ESRD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Stanford Medical Center Program in Multi-Organ Transplantation and the Division of Bone marrow Transplantation are enrolling patients into a research study to determine if donor stem cells given after a living related one Haplotype match kidney transplantation will change the immune system such that immunosuppressive drugs can be completely withdrawn.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal.
Busque S, Scandling JD, Lowsky R, Shizuru J, et al · · 2020 · cited 47× · PMID 31996467 · DOI 10.1126/scitranslmed.aax8863 -
Haploidentical mixed chimerism cures autoimmunity in established type 1 diabetic mice.
Liu Y, Wang X, Zhu Y, Zhang M, et al · · 2020 · cited 8× · PMID 32817590 · DOI 10.1172/jci131799 -
Development of immunosuppressive myeloid cells to induce tolerance in solid organ and hematopoietic cell transplant recipients.
Jensen KP, Hongo DA, Ji X, Zheng P, et al · · 2021 · cited 6× · PMID 34432869 · DOI 10.1182/bloodadvances.2020003669
Verify or expand the search:
- PubMed search for NCT01165762
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ESRD
Currently open trials in the same condition.
- NCT06913647 — Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis · Phase 2 · recruiting
- NCT06366230 — Adding Urea to the Final Dialysis Fluid · Phase 1, PHASE2 · recruiting
- NCT05339139 — SAfety of Regional Citrate Anticoagulation (SARCA Study) · Phase 3 · recruiting
- NCT05434325 — TESTING -ON Post-Trial ObservatioNal Cohort Study · recruiting
- NCT05309785 — Safety and Efficacy of Canagliflozin in Advanced CKD · Phase 4 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01165762 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Everett Meyer
- Last refreshed: 18 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01165762.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing